Swiss National Bank Alector, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Alector, Inc. stock. As of the latest transaction made, Swiss National Bank holds 131,900 shares of ALEC stock, worth $253,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares

131,900

Previous 131,900 -0.0%

Holding current value

$253,248

Previous $598,000 2.84%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$5.69 - $8.08 $45,520 - $64,640	8,000 Added 6.46%	131,900 $794,000
Q4 2023 Feb 06, 2024	SELL	$3.77 - $8.39 $44,109 - $98,163	-11,700 Reduced 8.63%	123,900 $988,000
Q2 2023 Aug 09, 2023	BUY	$5.86 - $7.93 $114,856 - $155,428	19,600 Added 16.9%	135,600 $814,000
Q1 2023 May 10, 2023	SELL	$5.85 - $9.84 $79,560 - $133,824	-13,600 Reduced 10.49%	116,000 $718,000
Q4 2022 Feb 08, 2023	BUY	$6.88 - $9.55 $18,576 - $25,785	2,700 Added 2.13%	129,600 $1.2 Million
Q3 2022 Nov 09, 2022	BUY	$8.19 - $13.2 $16,379 - $26,400	2,000 Added 1.6%	126,900 $1.2 Million
Q1 2022 May 09, 2022	BUY	$13.02 - $20.78 $119,784 - $191,176	9,200 Added 7.95%	124,900 $1.78 Million
Q4 2021 Feb 08, 2022	BUY	$19.35 - $25.54 $32,895 - $43,418	1,700 Added 1.49%	115,700 $2.39 Million
Q2 2021 Aug 06, 2021	BUY	$15.5 - $22.48 $223,200 - $323,712	14,400 Added 14.46%	114,000 $2.38 Million
Q1 2021 May 07, 2021	BUY	$14.84 - $22.23 $16,324 - $24,453	1,100 Added 1.12%	99,600 $2.01 Million
Q3 2020 Nov 09, 2020	BUY	$10.54 - $24.96 $15,809 - $37,440	1,500 Added 1.55%	98,500 $1.04 Million
Q2 2020 Aug 05, 2020	BUY	$21.87 - $33.11 $2.12 Million - $3.21 Million	97,000 New	97,000 $2.37 Million

Others Institutions Holding ALEC

# of Institutions

168

Shares Held

57.8M

Call Options Held

146K

Put Options Held

90.8K

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $159M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Alector, Inc. Transaction History